Siniscalco Dario, Sullo Nikol, Maione Sabatino, Rossi Francesco, D'Agostino Bruno
Department of Experimental Medicine, Section of Pharmacology, Second University of Naples, via S. Maria di Costantinopoli, 16-80138 Napoli, Italy.
Ther Adv Respir Dis. 2008 Jun;2(3):173-7. doi: 10.1177/1753465808092340.
Lung injuries are leading causes of morbidity and mortality worldwide. Pulmonary diseases such as asthma or chronic obstructive pulmonary disease characterized by loss of lung elasticity, small airway tethers, and luminal obstruction with inflammatory mucoid secretions, or idiopathic pulmonary fibrosis characterized by excessive matrix deposition and destruction of the normal lung architecture, have essentially symptomatic treatments and their management is costly to the health care system.Regeneration of tissue by stem cells from endogenous, exogenous, and even genetically modified cells is a promising novel therapy. The use of adult stem cells to help with lung regeneration and repair could be a newer technology in clinical and regenerative medicine. In fact, different studies have shown that bone marrow progenitor cells contribute to repair and remodeling of lung in animal models of progressive pulmonary hypertension.Therefore, lung stem cell biology may provide novel approaches to therapy and could represent a great promise for the future of molecular medicine. In fact, several diseases can be slowed or even blocked by stem cell transplantation.
肺部损伤是全球发病和死亡的主要原因。诸如哮喘或慢性阻塞性肺疾病等肺部疾病,其特征为肺弹性丧失、小气道束缚以及伴有炎性黏液样分泌物的管腔阻塞,或者特发性肺纤维化,其特征为基质过度沉积和正常肺结构破坏,目前基本上只有对症治疗,且其管理对医疗保健系统而言成本高昂。来自内源性、外源性甚至基因改造细胞的干细胞进行组织再生是一种有前景的新型疗法。使用成体干细胞来促进肺再生和修复可能是临床和再生医学中的一项新技术。事实上,不同的研究表明,在进行性肺动脉高压动物模型中,骨髓祖细胞有助于肺的修复和重塑。因此,肺干细胞生物学可能为治疗提供新方法,并且可能代表分子医学未来的巨大希望。事实上,几种疾病可以通过干细胞移植得到缓解甚至被阻断。